Key Xerostomia Therapeutics Market Players:
- GlaxoSmithKline plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Colgate-Palmolive Company
- Johnson & Johnson
- Sun Pharmaceutical Industries
- Eisai Co., Ltd.
- Novartis AG
- Pfizer Inc.
- Bayer AG
- Procter & Gamble
- Takeda Pharmaceutical
- Sanofi S.A.
- AstraZeneca plc
- Merck & Co., Inc.
- Hikma Pharmaceuticals PLC
- CSL Limited
- LG Chem Ltd.
- Cipla Ltd.
- Dabur India Ltd.
- Duopharma Biotech Berhad
- Aspen Pharmacare Holdings
The presence of both established and emerging players in the industry is fostering a standard landscape for the market to escalate. Global leaders such as GSK, Colgate-Palmolive, and Johnson & Johnson are leading the market with their brand recognition and extensive distribution. Besides, emerging nations such as India and Malaysia are witnessing growth owing to the presence of generic manufacturers such as Sun Pharma and Cipla. Further, firms are focused on research in saliva substitutes and investments in terms of biotech solutions to capture niche markets.
Here is a list of key players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of xerostomia therapeutics is evaluated at USD 1.89 billion.
xerostomia therapeutics market size was valued at approximately USD 1.89 billion in 2025 and is projected to reach around USD 2.78 billion by the end of 2035, rising at a CAGR of approximately 3.93% during the forecast period 2026-2035.
North America is a key player in the xerostomia therapeutics sector, projected to register a significant share of 45.7% in 2035.
The major players in the market are 3M Company, Colgate-Palmolive Co., Cumberland Pharmaceuticals Inc., GlaxoSmithKline Plc, Sun Pharmaceutical Industries Ltd., among others.
